Inventor · disambiguated record
Yasuhiro Funahashi
Also filed as: FUNAHASHI YASUHIRO
23 granted patents·13 pending applications·478 citations·filing 1999–2022
95Inventor score
Top patents by PatentIndex Score
36 records- 0197US7253286B2Nitrogen-containing aromatic derivativesEISAI CO LTD·Filed 2003·Granted Aug 7, 2007·207 cites·15 claims
- 0296US8372981B2Nitrogen-containing aromatic derivativesEISAI R&D MAN CO LTD·Filed 2011·Granted Feb 12, 2013·35 cites·2 claims
- 0395US7973160B2Nitrogen-containing aromatic derivativesEISAI R&D MAN CO LTD·Filed 2008·Granted Jul 5, 2011·38 cites·2 claims
- 0495US7612092B2Nitrogen-containing aromatic derivativesEISAI R&D MAN CO LTD·Filed 2005·Granted Nov 3, 2009·55 cites·18 claims
- 0594US11083705B2Pharmaceutical composition for treating tumorEISAI R&D MAN CO LTD·Filed 2020·Granted Aug 10, 2021·3 cites·17 claims
- 0693US6787534B2Sulfonamide-containing heterocyclic compoundsEISAI CO LTD·Filed 2000·Granted Sep 7, 2004·82 cites·9 claims
- 0790US7662919B2Notch-based fusion proteins and uses thereofUNIV COLUMBIA·Filed 2005·Granted Feb 16, 2010·8 cites·6 claims
- 0887US8962650B2Therapeutic agent for tumorNARITA YUSUKE·Filed 2012·Granted Feb 24, 2015·11 cites·10 claims
- 0980US10945990B2Combination of a PD-1 antagonist and eribulin for treating cancerMERCK SHARP & DOHME·Filed 2016·Granted Mar 16, 2021·6 cites·6 claims
- 1080US6469043B1Sulfonamide-containing indole compoundsEISAI CO LTD·Filed 2000·Granted Oct 22, 2002·13 cites·22 claims
- 1175US9945862B2Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compoundsFUNAHASHI YASUHIRO·Filed 2012·Granted Apr 17, 2018·6 cites·17 claims
- 1275US2023212679A1Method for Predicting Effectiveness of Angiogenesis InhibitorEISAI R&D MAN CO LTD·Filed 2022·Application pending·0 cites
- 1373US9012458B2Antitumor agent using compounds having kinase inhibitory effect in combinationNAKAGAWA TAKAYUKI·Filed 2011·Granted Apr 21, 2015·1 cites·9 claims
- 1470US6673787B2Sulfonamide-containing indole compoundsEISAI CO LTD·Filed 2002·Granted Jan 6, 2004·4 cites·19 claims
- 1568US6638964B2Sulfonamide-containing indole compoundsEISAI CO LTD·Filed 2002·Granted Oct 28, 2003·3 cites·9 claims
- 1667US12036204B2Pharmaceutical composition for treating tumorEISAI R&D MAN CO LTD·Filed 2021·Granted Jul 16, 2024·0 cites·18 claims
- 1767US10517861B2Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compoundsEISAI R&D MAN CO LTD·Filed 2014·Granted Dec 31, 2019·2 cites·15 claims
- 1867US2020199689A1Method for Predicting Effectiveness of Angiogenesis InhibitorEISAI R&D MAN CO LTD·Filed 2020·Application pending·0 cites
- 1962US2017191137A1Method For Predicting Effectiveness Of Angiogenesis InhibitorEISAI R&D MAN CO LTD·Filed 2017·Application pending·0 cites
- 2062US2021177802A1Pharmaceutical composition for treating tumorEISAI R&D MAN CO LTD·Filed 2021·Application pending·0 cites
- 2160US11598776B2Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compoundsEISAI R&D MAN CO LTD·Filed 2018·Granted Mar 7, 2023·0 cites·4 claims
- 2256US7122318B2Method for testing effect of angiogenesis inhibitor via integrin expression inhibitionEISAI CO LTD·Filed 2002·Granted Oct 17, 2006·3 cites·24 claims
- 2355US7834049B2Integrin expression inhibitorEISAI R&D MAN CO LTD·Filed 2005·Granted Nov 16, 2010·0 cites·4 claims
- 2453US2014148483A1Method For Predicting Effectiveness Of Angiogenesis InhibitorEISAI R&D MAN CO LTD·Filed 2012·Application pending·0 cites
- 2553US2022409724A1Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancerEISAI R&D MAN CO LTD·Filed 2020·Application pending·0 cites
- 2652US8993725B2Notch-based fusion proteins and uses thereofKITAJEWSKI JAN·Filed 2010·Granted Mar 31, 2015·0 cites·7 claims
- 2750US12504431B2Biomarkers for a therapy comprising a sorafenib compoundEISAI R&D MAN CO LTD·Filed 2019·Granted Dec 23, 2025·0 cites·12 claims
- 2850US2015329615A1Notch-based fusion proteins and uses thereofKITAJEWSKI JAN·Filed 2015·Application pending·0 cites
- 2947US2010267754A1Integrin expression inhibitorWAKABAYASHI TOSHIAKI·Filed 2010·Application pending·0 cites
- 3046US2004018192A1Integrin expression inhibitorsFiled 2001·Application pending·0 cites
- 3144US6649367B2Human cancer cell line malignantly altered by expression of angiogenic factorEISAI CO LTD·Filed 2002·Granted Nov 18, 2003·0 cites·6 claims
- 3238US2021349097A1Biomarkers for a combination therapy comprising lenvatinib and everolimusEISAI R&D MAN CO LTD·Filed 2019·Application pending·0 cites
- 3335US2018136216A1Biomarkers for a Combination Therapy Comprising Lenvatinib and EverolimusEISAI R&D MAN CO LTD·Filed 2016·Application pending·0 cites
- 3435US2021123919A1Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonistMERCK SHARP & DOHME·Filed 2019·Application pending·0 cites
- 3533US2017071903A1Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancerEISAI R&D MAN CO LTD·Filed 2015·Application pending·0 cites
- 3624US6645996B1Physiologically active substancesMERCIAN CORP AND EISAI CO LTD·Filed 1999·Granted Nov 11, 2003·1 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Yasuhiro Funahashi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →